Thermo Fisher Scientific(US:TMO) ZACKSยท2025-04-23 14:35Core Insights - Thermo Fisher Scientific reported revenue of $10.36 billion for the quarter ended March 2025, reflecting a year-over-year increase of 0.2% and an EPS of $5.15, up from $5.11 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $10.25 billion by 1.11%, while the EPS surpassed the consensus estimate of $5.10 by 0.98% [1] Revenue Performance - Organic revenue growth was 1%, compared to the average estimate of 0.2% from five analysts [4] - Life Sciences Solutions revenue was $2.34 billion, exceeding the estimated $2.28 billion, representing a year-over-year increase of 2.5% [4] - Analytical Instruments revenue was $1.72 billion, slightly below the estimated $1.73 billion, with a year-over-year increase of 1.8% [4] - Laboratory Products and Biopharma Services revenue was $5.64 billion, slightly above the estimated $5.61 billion, but showed a year-over-year decline of 1.5% [4] - Specialty Diagnostics revenue was $1.15 billion, surpassing the estimated $1.10 billion, with a year-over-year increase of 3.5% [4] - Revenues from Eliminations were reported at -$482 million, worse than the average estimate of -$449.31 million, but showed a year-over-year improvement of 4.8% [4] Stock Performance - Thermo Fisher's shares have returned -15.5% over the past month, compared to a -6.6% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]